Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of <sup>177</sup>Lu-DOTATATE PRRT

Eva Medaer(KU Leuven), Christophe M. Deroose(KU Leuven), Olivier Gheysens(Cliniques Universitaires Saint-Luc), Sander Jentjens(KU Leuven), Karolien Goffin(KU Leuven), Kristiaan Nackaerts(Heidelberg University), Annouschka Laenen(Statistics Belgium), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Koen Van Laere(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem, Paul M. Clément(Universitair Ziekenhuis Leuven)

Figshare

January 1, 2021

10.6084/m9.figshare.11826969

Cited by 0

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

|New England Journal of Medicine|2019|1.5k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.1k

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994